Evermore Global Advisors’s Enzo Biochem, Inc. ENZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-1,730,607
Closed -$6.13M 17
2021
Q3
$6.13M Hold
1,730,607
5.39% 9
2021
Q2
$5.49M Sell
1,730,607
-875,000
-34% -$2.75M 4.79% 8
2021
Q1
$8.96M Hold
2,605,607
6.32% 8
2020
Q4
$6.57M Sell
2,605,607
-344,597
-12% -$750K 7.1% 9
2020
Q3
$6.22M Sell
2,950,204
-266,500
-8% -$633K 5.64% 6
2020
Q2
$7.21M Sell
3,216,704
-791,147
-20% -$2.03M 3.55% 9
2020
Q1
$10.1M Hold
4,007,851
4.13% 9
2019
Q4
$10.5M Hold
4,007,851
2.35% 16
2019
Q3
$14.4M Buy
4,007,851
+420,600
+12% +$1.49M 3.48% 11
2019
Q2
$12.1M Sell
3,587,251
-999,168
-22% -$3.52M 2.28% 16
2019
Q1
$12.5M Buy
4,586,419
+58,600
+1% +$192K 1.97% 16
2018
Q4
$12.6M Sell
4,527,819
-34,485
-0.8% -$113K 2.06% 17
2018
Q3
$18.8M Sell
4,562,304
-185,600
-4% -$843K 2.4% 18
2018
Q2
$24.6M Buy
+4,747,904
New +$28.9M 3.07% 12
2017
Q4
Sell
-3,685,520
Closed -$38.6M 19
2017
Q3
$38.6M Buy
3,685,520
+130,287
+4% +$1.45M 5.96% 4
2017
Q2
$39.3M Buy
3,555,233
+242,441
+7% +$2.26M 9.97% 4
2017
Q1
$27.7M Hold
3,312,792
5.16% 7
2016
Q4
$23M Buy
+3,312,792
New +$21.1M 4.49% 7

Other funds holding ENZ

Evermore Global Advisors's ENZ Position: Q4 2021 in Review

Evermore Global Advisors sold out of Enzo Biochem, Inc. (ENZ) in Q4 2021, closing a stake of 1,730,607 shares — an estimated $6.13M sold.

Evermore Global Advisors first reported a position in ENZ in Q4 2016 and held it in 18 quarters. The position peaked at $39.3M in Q2 2017. 59 funds tracked by Wall St. Rank hold ENZ as of Q4 2021.

  • Evermore Global Advisors reported no remaining Enzo Biochem, Inc. position as of Q4 2021 after selling out during the quarter.
  • Evermore Global Advisors sold 1,730,607 Enzo Biochem, Inc. shares in Q4 2021, an estimated $6.13M.
  • Evermore Global Advisors first reported a position in Enzo Biochem, Inc. in Q4 2016 and held it in 18 quarters.
  • Evermore Global Advisors's Enzo Biochem, Inc. position peaked at $39.3M in Q2 2017.
  • 59 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q4 2021.

Based on Evermore Global Advisors's 13F filing for Q4 2021, filed 20 Jan 2022.